Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ethionamide + NADPH + H+ + O2
ethionamide S-oxide + NADP+ + H2O
-
-
-
?
hypotaurine + NADH + H+ + O2
taurine + NAD+ + H2O
S-oxygenation
-
-
?
hypotaurine + NADPH + H+ + O2
taurine + NADP+ + H2O
S-oxygenation
-
-
?
methimazole + NADPH + H+ + O2
methimazole S-oxide + NADP+ + H2O
S-oxygenation
-
-
?
N,N-dimethylaniline + NADPH + H+ + O2
N,N-dimethylaniline N-oxide + NADP+ + H2O
-
-
-
?
1-butanethiol + NADPH + O2
?
-
-
-
-
?
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + NADPH + H+ + O2
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine N-oxide + NADP+ + H2O
10-(N,N-dimethylaminooctyl)2-(trifluoromethyl)phenothiazene + NADPH + H+ + O2
? + NADP+ + H2O
-
-
-
?
10-(N,N-dimethylaminooctyl)2-(trifluoromethyl)phenothiazine + NADPH + H+ + O2
10-(N,N-dimethylaminooctyl)2-(trifluoromethyl)phenothiazine N-oxide + NADP+ + H2O
-
-
-
r
2-acetylsulfanylmethyl-4-(4-methoxyphenyl)-4-oxobutyric acid + NADPH + H+ + O2
?
-
-
-
-
?
2-mercaptobenzimidazole + NADPH + O2
?
-
-
-
-
?
2-[2-(4-methoxyphenyl)-2-oxoethyl]-acrylic acid + NADPH + H+ + O2
?
-
a synthetic 10-(N,N-dimethylaminoalkyl)-2-(trifluoromethyl)phenothiazine analogue
-
-
?
4-(4-methoxyphenyl)-2-methylsulfanylmethyl-4-oxobutyric acid + NADPH + H+ + O2
?
-
FMO1, poor activity with FMO3 and FMO5
-
-
?
4-(4-methylphenyl)-2-methylsulfanylmethyl-4-oxobutyric acid + NADPH + H+ + O2
?
-
FMO1 and FMO5, no activity with FMO3
-
-
?
alpha-naphthylthiourea + NADPH + O2
?
-
-
-
-
?
aminopyrine + NADPH + O2
?
-
-
-
-
?
benzydamine + NADPH + H+ + O2
benzydamine N-oxide + NADP+ + H2O
-
substrate of isoforms FMO1 and FMO3
-
-
?
cysteamine + NADPH + O2
?
-
-
-
-
?
cysteamine + NADPH + O2
cysteamine N-oxide + NADP+ + H2O
-
-
-
-
?
dibenzylamine + NADPH + O2
?
-
-
-
-
?
ephedrine + NADPH + O2
?
-
-
-
-
?
ethionamide + NADPH + H+ + O2
ethionamide N-oxide + NADP+ + H2O
-
-
-
?
ethionamide + NADPH + H+ + O2
ethionamide S-oxide + NADP+ + H2O
ethylene sulfide + NADPH + O2
?
-
-
-
-
?
imipramine + NADPH + H+ + O2
imipramine N-oxide + NADP+ + H2O
-
substrate of isoform FMO1
-
-
?
imipramine + NADPH + O2
?
-
-
-
-
?
mercaptoimidazole + NADPH + H+ + O2
?
-
FMO1 and FMO3, no activity with FMO5
-
-
?
methamphetamine + NADPH + O2
?
-
-
-
-
?
methimazole + NADPH + H+ + O2
?
-
FMO1, FMO2, and FMO3
-
-
?
methimazole + NADPH + O2
N-methylmethimidazole-2-sulfinic acid + NADP+ + H2O
-
-
-
-
?
methyl 4-tolyl sulfide + NADPH + O2
methyl 4-tolyl sulfoxide + NADP+ + H2O
-
-
-
-
?
methyl p-tolyl sulfide + NADPH + H+ + O2
?
-
FMO1, FMO2, but poor substrate of FMO3
-
-
?
methylphenylsulfide + NADPH + O2
?
-
-
-
-
?
N,N-dimethyl-3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propan-1-amine + NADPH + H+ + O2
?
-
3-DPT, a phenothiazine analogue, N-oxygenation by FMO1 and FMO3, no activity with FMO5
-
-
?
N,N-dimethyl-5-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]pentan-1-amine + NADPH + H+ + O2
?
-
5-DPT, a phenothiazine analogue, N-oxygenation by FMO1, FMO3, and FMO5
-
-
?
N,N-dimethyl-8-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]octan-1-amine + NADPH + H+ + O2
?
-
8-DPT, a phenothiazine analogue, N-oxygenation by FMO1, FMO3, and FMO5
-
-
?
N,N-dimethylaniline + NADPH + O2
N,N-dimethylaniline N-oxide + NADP+ + H2O
-
-
-
-
?
N-aminopiperidine + NADPH + O2
tetrazene + NADP+ + H2O + ?
-
-
-
-
?
n-decylamine + NADPH + O2
1-nitrosodecane + NADP+ + H2O
-
lung enzyme active, liver enzyme not
-
-
?
n-octylamine + NADPH + O2
1-nitrosooctane + NADP+ + H2O
-
lung enzyme active, liver enzyme not
-
-
?
p-chloro-N-methylaniline + NADPH + O2
?
-
-
-
-
?
pentoxifylline + NADPH + H+ + O2
pentoxifylline N-oxide + NADP+ + H2O
-
-
-
?
phenylthiourea + NADPH + O2
?
-
-
-
-
?
S-methyl esonarimod + NADPH + H+ + O2
?
-
-
-
-
?
sulindac sulfide + NADPH + H+ + O2
sulindac + NADP+ + H2O
-
-
-
?
tamoxifen + NADPH + O2
tamoxifen N-oxide + NADP+ + H2O
thioacetamide + NADPH + O2
?
-
-
-
-
?
thiobenzamide + NADPH + O2
?
-
-
-
-
?
thiourea + NADPH + O2
?
-
-
-
-
?
trimethylamine + NADPH + H+ + O2
?
-
FMO1, no activity with FMO3 and FMO5
-
-
?
trimethylamine + NADPH + O2
?
-
-
-
-
?
trimethylamine + NADPH + O2
trimethylamine N-oxide + NADP+ + H2O
-
-
-
-
?
voriconazole + NADPH + H+ + O2
?
-
-
-
-
?
additional information
?
-
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + NADPH + H+ + O2
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine N-oxide + NADP+ + H2O
-
-
-
?
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + NADPH + H+ + O2
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine N-oxide + NADP+ + H2O
-
reaction in microsomal detoxification pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a neurotoxin to nigrostriatal dopaminergic neurons
-
-
?
ethionamide + NADPH + H+ + O2
ethionamide S-oxide + NADP+ + H2O
-
-
-
?
ethionamide + NADPH + H+ + O2
ethionamide S-oxide + NADP+ + H2O
ethionamide is a pro-drug requiring bioactivation to exert toxicity
-
-
?
ethionamide + NADPH + H+ + O2
ethionamide S-oxide + NADP+ + H2O
i.e. ETA, S-oxygenation by isozymes FMO1, FMO2, and FMO3
-
-
?
tamoxifen + NADPH + O2
tamoxifen N-oxide + NADP+ + H2O
-
tamoxifen N-oxygenation represents a detoxication pathway, high activity by isozyme FMO1
-
-
?
tamoxifen + NADPH + O2
tamoxifen N-oxide + NADP+ + H2O
-
i.e. Z-(1-[4-(2-dimethyl-aminoethoxy)phenyl]-1,2-diphenyl-1-butene)
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
-
overview on specificity
-
-
?
additional information
?
-
-
FMO oxygenates a number of drugs and xenobiotics containing a soft-nucleophile heteroatom, mostly sulfur- and nitrogen-containing xenobiotics, and is involved in detoxication
-
-
?
additional information
?
-
-
nitrogen- and sulfur-containing endogenous substrates and physiologic functions, the enzyme is involved in detoxification and drug metabolism, overview, hepatic total FMO activity is enhanced in mouse models of type I and type II diabetes
-
-
?
additional information
?
-
-
the enzyme is involved in fatty acid oxidation in the liver, as well as in drug detoxification
-
-
?
additional information
?
-
-
regulation of hepatic Fmo isozymes, overview
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
in vitro microsomal Baeyer-Villiger oxidation of pentoxifylline (PTX) by Fmo5
-
-
-
additional information
?
-
-
in vitro microsomal Baeyer-Villiger oxidation of pentoxifylline (PTX) by Fmo5
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
hypotaurine + NADH + H+ + O2
taurine + NAD+ + H2O
S-oxygenation
-
-
?
hypotaurine + NADPH + H+ + O2
taurine + NADP+ + H2O
S-oxygenation
-
-
?
N,N-dimethylaniline + NADPH + H+ + O2
N,N-dimethylaniline N-oxide + NADP+ + H2O
-
-
-
?
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + NADPH + H+ + O2
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine N-oxide + NADP+ + H2O
-
reaction in microsomal detoxification pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a neurotoxin to nigrostriatal dopaminergic neurons
-
-
?
cysteamine + NADPH + O2
cysteamine N-oxide + NADP+ + H2O
-
-
-
-
?
ethionamide + NADPH + H+ + O2
ethionamide S-oxide + NADP+ + H2O
ethionamide is a pro-drug requiring bioactivation to exert toxicity
-
-
?
N,N-dimethylaniline + NADPH + O2
N,N-dimethylaniline N-oxide + NADP+ + H2O
-
-
-
-
?
tamoxifen + NADPH + O2
tamoxifen N-oxide + NADP+ + H2O
-
tamoxifen N-oxygenation represents a detoxication pathway, high activity by isozyme FMO1
-
-
?
trimethylamine + NADPH + O2
trimethylamine N-oxide + NADP+ + H2O
-
-
-
-
?
additional information
?
-
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
-
FMO oxygenates a number of drugs and xenobiotics containing a soft-nucleophile heteroatom, mostly sulfur- and nitrogen-containing xenobiotics, and is involved in detoxication
-
-
?
additional information
?
-
-
nitrogen- and sulfur-containing endogenous substrates and physiologic functions, the enzyme is involved in detoxification and drug metabolism, overview, hepatic total FMO activity is enhanced in mouse models of type I and type II diabetes
-
-
?
additional information
?
-
-
the enzyme is involved in fatty acid oxidation in the liver, as well as in drug detoxification
-
-
?
additional information
?
-
-
regulation of hepatic Fmo isozymes, overview
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
additional information
?
-
-
flavin-containing monooxygenases catalyze the addition of oxygen to many sulfur-, nitrogen-, phosphorus-, and selenium-containing compounds including pesticides, therapeutics, and dietary substances
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
malfunction
FMO1 malfunction causes taurine deficiency, which is implicated in a number of pathologic conditions, including cardiomyopathy, muscular abnormalities, and renal dysfunction
physiological function
the formation of taurine from hypotaurine is catalyzed by an FMO in vivo, it is the terminal step of the biosynthetic pathway of taurine production from cysteine
malfunction
-
enzyme-deficient mice are resistant to age-related changes in glucose homeostasis and maintain the higher glucose tolerance and insulin sensitivity characteristic of young animals
metabolism
the enzyme is involved in metabolism of the anti-tuberculosis drug ethionamide in lung and liver, overview
metabolism
-
isoform FMO3 contribute a major part in busulphan metabolic pathway
physiological function
-
flavin-containing monooxygenase 3 reduces endoplasmic reticulum stress in palmitate-treated hepatocytes. The enzyme can contribute to the regulation of glucose metabolism in the liver by reducing lipid-induced endoplasmic reticulum stress and the expression of phosphoenolpyruvate carboxykinase, independently of insulin signal transduction
physiological function
-
the enzyme plays a role in sensing or responding to gut bacteria and is a regulator of body weight and of glucose disposal and insulin sensitivity
physiological function
flavin-containing monooxygenases (FMOs) are a family of phase I enzymes involved in metabolism of numerous drugs (e.g. benzydamine, methimazole, and albendazole) and environmental toxicants (e.g. insecticides, fonfos, and aldicarb). Flavin-containing monooxygenase 5 (FMO5) is a phase I enzyme that plays an important role in xenobiotic metabolism. Analysis of the diurnal rhythms of Fmo5 expression and activity in mouse liver and of the potential roles of clock genes (Bmal1, Rev-erba, and E4bp4) in the generation of diurnal rhythms. Fmo5 mRNA and protein show robust diurnal rhythms, with peak values at zeitgeber time (ZT) 10/14 and trough values at ZT2/22 in mouse liver. Bmal1 (a known Rev-erba activator) activates Fmo5 transcription via direct binding to an E-box (21822/21816 bp) in the promoter, whereas E4bp4 (a known Rev-erba target gene) inhibits Fmo5 transcription by binding to two D-boxes (21726/21718 and 2804/2796 bp). In conclusion, circadian clock genes control diurnal expression of Fmo5 through transcriptional actions on E-box and D-box cis-elements. Circadian time-dependent in vivo activity of Fmo5, molecular mechanism for generation of rhythmic Fmo5 expression, detailed overview. Human FMO5 specifically catalyzes the formation of an oxidized metabolite (PTX-M) from PTX, also known as a Baeyer-Villiger oxidation reaction
additional information
chromatin immunoprecipitation assays do not detect recruitment of aryl hydrocarbon receptor or ARNT to Fmo3 regulatory elements after exposure to 3-methylcholanthrene in liver or in Hepa-1 cells. However, in Hepa-1, 3-methylcholanthrene and benzo[a]pyrene , but not 2,3,7,8-tetrachlorodibenzo-p-dioxin, cause recruitment of p53 protein to a p53 response element in the 5'-flanking region of the Fmo3 gene. Although FMO3 mRNA is highly induced by 3-methylcholanthrene or 2,3,7,8-tetrachlorodibenzo-p-dioxin in mouse liver and in Hepa-1 cells, FMO protein levels and FMO catalytic function show only modest elevation
additional information
-
chromatin immunoprecipitation assays do not detect recruitment of aryl hydrocarbon receptor or ARNT to Fmo3 regulatory elements after exposure to 3-methylcholanthrene in liver or in Hepa-1 cells. However, in Hepa-1, 3-methylcholanthrene and benzo[a]pyrene , but not 2,3,7,8-tetrachlorodibenzo-p-dioxin, cause recruitment of p53 protein to a p53 response element in the 5'-flanking region of the Fmo3 gene. Although FMO3 mRNA is highly induced by 3-methylcholanthrene or 2,3,7,8-tetrachlorodibenzo-p-dioxin in mouse liver and in Hepa-1 cells, FMO protein levels and FMO catalytic function show only modest elevation
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
isozyme Fmo1 is not affected by 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure or castration in contrast to other Fmo isozymes, overview
8fold induction of FMO3 in liver by 3-methylcholanthrene. In Hepa-1 cells, 3-methylcholanthrene and benzo[a]pyrene induce FMO3 mRNA by about 30fold in an aryl hydrocarbon receptor-dependent manner. Aryl hydrocarbon receptor, AHR, dependent induction of FMO mRNAs in liver by 2,3,7,8-tetrachlorodibenzo-p-dioxin, but the potent AHR agonist, TCDD, does not induce FMO3 mRNA in Hepa-1 cells. Mechanism of FMO3 mRNA induction, overview
analysis of the diurnal rhythms of Fmo5 expression and activity in mouse liver and of the potential roles of clock genes (Bmal1, Rev-erba, and E4bp4) in the generation of diurnal rhythms. Fmo5 mRNA and protein show robust diurnal rhythms, with peak values at zeitgeber time (ZT) 10/14 and trough values at ZT2/22 in mouse liver. Bmal1 (a known Rev-erba activator) activates Fmo5 transcription via direct binding to an E-box (21822/21816 bp) in the promoter, whereas E4bp4 (a known Rev-erba target gene) inhibits Fmo5 transcription by binding to two D-boxes (21726/21718 and 2804/2796 bp). In conclusion, circadian clock genes control diurnal expression of Fmo5 through transcriptional actions on E-box and D-box cis-elements
in female mice, testosterone plays a role in negative FMO regulation
-
isozyme expressions, especially of Fmo3, are downregulated by lipopolysaccharides or infection with Citrobacter rodentium in inflammation female C3H/HeOuJ mouse models, which is independent of Toll-like receptor 4, TLR4, overview
-
isozyme Fmo1 is not affected by 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure or castration in contrast to other Fmo isozymes, overview
isozyme Fmo2 is induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure or castration, 5fold and 20fold, respectively
isozyme Fmo3 is induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure or castration, 130fold and 180fold, respectively
isozyme Fmo4 is induced by castration, but not by exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin
liver FMO1 is upregulated in diabetic mice
-
no induction of FMO3 in Hepa-1 cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin, DMSO, beta-naphthoflavon, 3,3',4,4',5-pentachlorobiphenyl, butylated hydroxyanisole, menadione, sulphoraphane, and tert-butylhydroquinone
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Tynes, R.E.; Sabourin, P.J.; Hodgson, E.
Identification of distinct hepatic and pulmonary forms of microsomal flavin-containing monooxygenase in the mouse and rabbit
Biochem. Biophys. Res. Commun.
126
1069-1075
1985
Oryctolagus cuniculus, Mus musculus
brenda
Tynes, R.E.; Hodgson, E.
Catalytic activity and substrate specificity of the flavin-containing monooxygenase in microsomal systems: characterization of the hepatic, pulmonary and renal enzymes of the mouse, rabbit, and rat
Arch. Biochem. Biophys.
240
77-93
1985
Oryctolagus cuniculus, Mus musculus, Rattus norvegicus, Sus scrofa
brenda
Chiba, K.; Kubota, E.; Miyakawa, T.; Kato, Y.; Ishizaki, T.
Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
J. Pharmacol. Exp. Ther.
246
1108-1115
1988
Mus musculus, Mus musculus C-57 BL
brenda
Di Monte, D.A.; Wu, E.Y.; Irwin, I.; Delanney, L.E.; Langston, J.W.
Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes
J. Pharmacol. Exp. Ther.
258
594-600
1991
Mus musculus
brenda
Rasooly, R.; Kelley, D.S.; Greg, J.; Mackey, B.E.
Dietary trans 10, cis 12-conjugated linoleic acid reduces the expression of fatty acid oxidation and drug detoxification enzymes in mouse liver
Br. J. Nutr.
97
58-66
2007
Mus musculus
brenda
Krueger, S.K.; Vandyke, J.E.; Williams, D.E.; Hines, R.N.
The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines
Drug Metab. Rev.
38
139-147
2006
Homo sapiens, Mus musculus, Rattus norvegicus, Sus scrofa
brenda
Krueger, S.K.; Williams, D.E.
Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism
Pharmacol. Ther.
106
357-387
2005
Oryctolagus cuniculus, Homo sapiens, Mus musculus, Sus scrofa
brenda
Shephard, E.A.; Chandan, P.; Stevanovic-Walker, M.; Edwards, M.; Phillips, I.R.
Alternative promoters and repetitive DNA elements define the species-dependent tissue-specific expression of the FMO1 genes of human and mouse
Biochem. J.
406
491-499
2007
Mus musculus (P50285), Mus musculus, Homo sapiens (Q01740), Homo sapiens
brenda
Siddens, L.K.; Henderson, M.C.; Vandyke, J.E.; Williams, D.E.; Krueger, S.K.
Characterization of mouse flavin-containing monooxygenase transcript levels in lung and liver, and activity of expressed isoforms
Biochem. Pharmacol.
75
570-579
2008
Mus musculus
brenda
Zhang, J.; Cerny, M.A.; Lawson, M.; Mosadeghi, R.; Cashman, J.R.
Functional activity of the mouse flavin-containing monooxygenase forms 1, 3, and 5
J. Biochem. Mol. Toxicol.
21
206-215
2007
Mus musculus
brenda
Mitchell, S.
Flavin mono-oxygenase (FMO) - The other oxidase
Curr. Drug Metab.
9
280-284
2008
Oryctolagus cuniculus, Homo sapiens, Mus musculus, Rattus norvegicus, Sus scrofa
brenda
Zhang, J.; Chaluvadi, M.R.; Reddy, R.; Motika, M.S.; Richardson, T.A.; Cashman, J.R.; Morgan, E.T.
Hepatic flavin-containing monooxygenase gene regulation in different mouse inflammation models
Drug Metab. Dispos.
37
462-468
2009
Mus musculus
brenda
Novick, R.M.; Mitzey, A.M.; Brownfield, M.S.; Elfarra, A.A.
Differential localization of flavin-containing monooxygenase (FMO) isoforms 1, 3, and 4 in rat liver and kidney and evidence for expression of FMO4 in mouse, rat, and human liver and kidney microsomes
J. Pharmacol. Exp. Ther.
329
1148-1155
2009
Homo sapiens, Homo sapiens (P31512), Mus musculus, Rattus norvegicus (P36365), Rattus norvegicus (Q8K4B7), Rattus norvegicus (Q9EQ76)
brenda
Henderson, M.C.; Siddens, L.K.; Morre, J.T.; Krueger, S.K.; Williams, D.E.
Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes
Toxicol. Appl. Pharmacol.
233
420-427
2008
Homo sapiens, Homo sapiens (Q01740), Homo sapiens (Q99518), Mus musculus, Mus musculus (P50285), Mus musculus (Q8K2I3)
brenda
Novick, R.; Vezina, C.; Elfarra, A.
Isoform distinct time-, dose-, and castration-dependent alterations in flavin-containing monooxygenase expression in mouse liver after 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment
Biochem. Pharmacol.
79
1345-1351
2010
Mus musculus (P50285), Mus musculus (P97501), Mus musculus (P97872), Mus musculus (Q8K2I3), Mus musculus (Q8VHG0), Mus musculus, Mus musculus C57/BL6J (P50285), Mus musculus C57/BL6J (P97501), Mus musculus C57/BL6J (P97872), Mus musculus C57/BL6J (Q8K2I3), Mus musculus C57/BL6J (Q8VHG0)
brenda
Celius, T.; Pansoy, A.; Matthews, J.; Okey, A.B.; Henderson, M.C.; Krueger, S.K.; Williams, D.E.
Flavin-containing monooxygenase-3: induction by 3-methylcholanthrene and complex regulation by xenobiotic chemicals in hepatoma cells and mouse liver
Toxicol. Appl. Pharmacol.
247
60-69
2010
Mus musculus (P97501), Mus musculus
brenda
Motika, M.S.; Zhang, J.; Ralph, E.C.; Dwyer, M.A.; Cashman, J.R.
pH dependence on functional activity of human and mouse flavin-containing monooxygenase 5
Biochem. Pharmacol.
83
962-968
2012
Homo sapiens (P49326), Homo sapiens, Mus musculus (P97872), Mus musculus
brenda
Tanino, T.; Bando, T.; Komada, A.; Nojiri, Y.; Okada, Y.; Ueda, Y.; Sakurai, E.
Hepatic flavin-containing monooxygenase 3 enzyme suppressed by type 1 allergy-produced nitric oxide
Drug Metab. Dispos.
45
1189-1196
2017
Mus musculus
brenda
Scott, F.; Gonzalez Malagon, S.G.; OBrien, B.A.; Fennema, D.; Veeravalli, S.; Coveney, C.R.; Phillips, I.R.; Shephard, E.A.
Identification of flavin-containing monooxygenase 5 (FMO5) as a regulator of glucose homeostasis and a potential sensor of gut bacteria
Drug Metab. Dispos.
45
982-989
2017
Mus musculus
brenda
Phillips, I.R.; Shephard, E.A.
Drug metabolism by flavin-containing monooxygenases of human and mouse
Expert. Opin. Drug Metab. Toxicol.
13
167-181
2017
Homo sapiens, Mus musculus
brenda
Liao, B.M.; McManus, S.A.; Hughes, W.E.; Schmitz-Peiffer, C.
Flavin-containing monooxygenase 3 reduces endoplasmic reticulum stress in lipid-treated hepatocytes
Mol. Endocrinol.
30
417-428
2016
Homo sapiens, Mus musculus
brenda
El-Serafi, I.; Terelius, Y.; Abedi-Valugerdi, M.; Naughton, S.; Saghafian, M.; Moshfegh, A.; Mattsson, J.; Potacova, Z.; Hassan, M.
Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway
PLoS ONE
12
e0187294
2017
Homo sapiens, Mus musculus
brenda
Chen, M.; Guan, B.; Xu, H.; Yu, F.; Zhang, T.; Wu, B.
The molecular mechanism regulating diurnal rhythm of flavin-containing monooxygenase 5 in mouse liver
Drug Metab. Dispos.
47
1333-1342
2019
Mus musculus (P97872), Mus musculus, Mus musculus C57BL/6 (P97872)
brenda
Veeravalli, S.; Phillips, I.R.; Freire, R.T.; Varshavi, D.; Everett, J.R.; Shephard, E.A.
Flavin-containing monooxygenase 1 catalyzes the production of taurine from hypotaurine
Drug Metab. Dispos.
48
378-385
2020
Homo sapiens, Homo sapiens (Q01740), Mus musculus (P50285)
brenda